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Introduction: Natural killer (NK) cells are a promising tool for
adoptive immunotherapy in many disease settings. The avail-
ability of large quantities of functionally effective NK cells
represents oneof themajor challenges for immunotherapeutic
trials, and amajor objective of our laboratory is to enhance NK
cell number and function ex vivo for subsequent adoptive
immunotherapy. We previously published a robust approach
for ex vivo propagation of NK cells that has been validated for
healthy donor (Denman, 2012) and patient peripheral blood
(Liu, 2013), cord blood (ASH 2012), and embryonic/pleur-
ipotent stem cell sources (Knorr 2013) and has the potential to
generate far more NK cells than can be infused at one time.
Cryopreservation of NK cells provides signiﬁcant advantages
over infusion of fresh products by 1) reducing timing con-
straints in matching GMP manufacturing to patient need, 2)
enabling multiple infusions from single large-scale expan-
sions, and3)ensuringuniformcharacteristics foraliquots, all of
which are essential for generating off-the-shelf products.
However, NK cells are known to have poor survival and func-
tion after cryopreservation, and thiswas recently conﬁrmed in
clinical trials using standard clinical GMP cryopreservation
media containing Plasmalyte, dimethyl sulfoxide (DMSO), and
human serum albumin (HSA). In contrast, our preclinical data
with expanded NK cells cryopreserved in media, fetal bovine
serum (FBS) and DMSO showed excellent function and no
signiﬁcant difference between fresh and frozen cells (Liu,
2013). Therefore, we hypothesized that serum may provide
protective factors for NK cells during cryopreservation.
Methods: NK cells from four healthy donors were expanded
withweekly addition of irradiated K562 Clone9.mbIL21 feeder
cells as previously described. After three weeks, cells were
cryopreserved with freezing media of 40% Plasmalyte and 10%
DMSO, with varying ratios of HSA and human AB serum (hAB)
comprising the remainder. Cryopreserved NK cells were
thawed and assessed for cell recovery, viability, proliferation,
and function at 3, 24, 48, 72,120, 168 hours after thawing.
Cytotoxicity was determined against 721.221 target cells.
Results: A linear relationship was observed between hAB
content and recovery, viability, and cytotoxicity, plateauing
at 40% hAB. Unstimulated proliferation after thawing was
associated with higher hAB content, but re-stimulation with
Clone9.mbIL21 was similar in all conditions.
Conclusion: In the present study, we aimed to establish the
beneﬁt of including serum incryopreservationof expandedNK
cell. We conﬁrmed a signiﬁcant effect in preserving viability,
cytotoxicity, andproliferation, justifying its use inclinical trials.Baseline scan
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Background: Allogeneic transplantation is associated with
both GvL and GvHD. Elimination of donor T cells results in
less GvHD, but also less GvL and engraftment. To eradicate
infused T cells if GvHD develops, our suicide gene based
therapy uses a CD34-Herpes Simplex Virus-1-thymidine ki-
nase (CD34-TK75) chimera (Rettig et al, Mol Ther 2003 and J
Immunol 2006). We enrich and purify retrovirally trans-
duced cells via cell surface expression of the extracellular
domain of CD34. Modiﬁed TK75 both mediates cell suicide
upon treatment with ganciclovir and enables tracking of
modiﬁed cells that entrap the substrate, [18CT/CT.
Methods: Following production and release testing of CD34-
TK75 transduced and afﬁnity-puriﬁed T cells (88-98.8%
CD34+), we began a phase I pilot and feasibility study. Cells
were infused as a DLI (0.1-1.3 x 106 CD34-TK75+ T cells/kg)
into 8 patients (relapsed after allo-HSCT). Since no toxicities
were observed during treatment of our ﬁrst 2 patients, we
initiated trafﬁcking studies using [18F]-FHBG-PET/CT imaging
at baseline, d15, and d30 after infusion of CD34TK75+ T cells
in patients 3-8.
Results: No acute toxicities were associated with adminis-
tering either genetically modiﬁed T cells or [18F]FHBG. Using
real-time quantitative PCR, we detected the CD34-TK75
transgene in the circulating CD34-TK75+ T cells of all but one
patient. GvHD developed in only one patient (grade III GI)
who did not respond to a 10 day treatment with I.V. ganci-
clovir (10 mg/kg). CD34-TK75 transgene could not be
detected in the peripheral blood of this patient at the time of
GvHD. Patient samples were also tested for replication
competent retrovirus and for integration sites both by Liga-
tion Mediated-PCR and hybrid capture. Baseline levels of
[18F]FHBG were low, primarily characterized by renal excre-
tion, which should permit detection of T cell expansion in the
lymphoid organs or intestines. However, pharmacokinetics
of the radiolabel were similar in the one patient that did and
those that did not develop GvHD (Fig. 1). In parallel experi-
ments, NOD/SCIDg mice were injected (i.o.) with 2 x 106
CD34-TK75+ T cells (patients 2-8; n¼2 mice per donor).
Control mice received conditioning only. Using micro-PET/CT
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the thymus and lymph nodes only in mice that developed
GvHD.
Summary: This "ﬁrst-in-man" study demonstrated the
safety and feasibility of manufacturing both CD34-TK75+ T
cells and [18F]FHBG onsite for administration to patients. A
future upfront haploidentical transplant study will employ
100-fold more CD34-TK75 modiﬁed T cells.Table I
T-Rapa12 DLI T-Rapa6 DLI
Patient Characteristics
Number of Patients 40 44
Age (median, range) 51 (23-69) 48 (26-70)
# Prior Regimens (median, range) 3 (1-5) 3 (1-8)
Non-Hodgkins 19 (47.5%) 23 (52.3%)
Hodgkins/Gray Zone 6 (15.0%) 11 (25.0%)
Other Heme Malignancy 15 (37.5%) 10 (22.7%)
Diagnostic Risk Group, Kahl I 9 (22.5%) 7 (15.9%)
Kahl II 7 (17.5%) 8 (18.2%)
Kahl III 24 (60.0%) 29 (65.9%)
Chemotherapy Refractory 20 (50%) 21 (47.7%)
Kahl III and/or Refractory 29 (72.5%) 36 (81.8%)
Complete Remission (at HCT) 8 (20%) 12 (27.3%)
Chimerism (% donor; median
values)
Day 14 Post-HCT 60%T 35%
Myeloid
44% T 35%
Myeloid
Day 28 Post-HCT 87% T 79%
Myeloid
78%T 85%
Myeloid
Day 100 Past- HCT 94% T 99%
Myeloid
97% T 100%
Myeloid
GVHD
Classical Acute (through day 100) 4/40 (10%) 17/42 (40.5%)176
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In vitro CD34 enrichment of stem cell grafts is widely used for
depleting T cells from the graft. A high ex vivoT cell depletion
enables effective prevention of Graft-Versus Host Disease
(GVHD) e a major complication after allogeneic stem cell
transplantation. Until now, the clinical scale enrichment of
CD34 positive cells is a complex procedure involving
numerous manual steps.
We have developed a fully automated clinical scale process
within a closed sterile system to purify CD34+cells from
human leukapheresis products. In this context, cell washing,
erythrocyte reduction, cell labeling and the conditions for
immunomagnetic separation were optimized.
To determine the process performance, CD34+cells were
separated fromhuman leukapheresis products with an initial
volume of 120 mL to 211 mL (n¼5). We performed colony-
forming unit (CFU) assays, which allowed us to evaluate the
differentiation potential of the enriched cells.
The total processing time was <4 h. The number of enriched
CD34+ cells was 5.4x106 (range: 2.6x106 to 9.8x106). The
average yield was 73% and the average viability of the sepa-
rated CD34+ cells achieved 76% (range: 65.0% to 85.0%). The
depletion of CD34 negative cells was >99.9%. CFU assays per-
formed after the fully automated enrichment process showed
that the CD34+cell fraction contained primitive and multi-
potent progenitor cells, such as CFU-GEMM and CFU-GM.
The cell separation system described provides a safe and easy
way to purify CD34+ cells from leukapheresis within <4 h
without any intermediatemanual steps. The cell preparation in
a closed sterile system facilitates a fast and robust enrichment
ofCD34+cells.Thecells areeluted inavolumeofapproximately
80 mL and can be used directly for further applications.Acute GVHD Grade II (n¼3); III (n¼1) II (n¼14); III
(n¼3)
Acute GVHD Through Day 180,
Total
15/39 (38.5%) 28/42 (66.7%)
Gut involvement 7/39 (17.9%) 30/42 (47.6%)
Median Day of Onset Day 92 Day 70
Classical Chronic 17/37 (45.9%) 17/36 (47.2%)
(60 month
median F/U)
(38 month
median F/U)
Overall Outcome
K-M Survival Probability, Day 100
Post-HCT
95% 93.2%
One-year Post-HCT 75% 79.6%
Two-year Post-HCT 67.5% 63.6%
Current Survival, Overall 21/40 (52.5%) 28/44 (63.6%)
In Sustained CR 18/40 (45%) 21/44 (47.7%)
Death Due to PD (% of all patients) 17/40 (42.5%) 11/44 (25%)
In PR/CR (TRM) 2/40 (5.0%) 3/44 (6.8%)177
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In a phase II clinical trial, pre-emptive DLI using rapamycin-
resistant donor CD4+ T cells manufactured in 12-days
(T-Rapa12 cells) was associated with conversion of mixed
chimerism, GVL effects in patients with refractory hemato-
logic malignancy, and a moderate rate and severity of GVHD
(Blood, 2013). We recently found that culture interval trun-
cation to 6-days yielded T-Rapa6 cells with a unique gene
expression proﬁle (w6% of genes differentially expressed
relative to T-Rapa12 cells; Cytotherapy, 2013). To assess
whether T-Rapa6 cells mediate distinct clinical effects rela-
tive to T-Rapa12 cells, we conducted a sequential phase II
clinical trial (NCT0074490) at the NIH and Hackensack Uni-
versity Medical Center using the exact same low-intensity
transplant platform. T-Rapa6 cells were manufactured by ex
